SOURCE: CymaBay Therapeutics

CymaBay Therapeutics Logo

November 26, 2014 14:43 ET

CymaBay Therapeutics to Present at the Piper Jaffray 26th Annual Healthcare Conference

NEWARK, CA--(Marketwired - November 26, 2014) - CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that senior management will present an overview of the company on Tuesday, December 2, at 1:10 p.m. ET at the Piper Jaffray 26th Annual Healthcare Conference (New York, December 2-3).

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in Phase 2a gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of serum uric acid (sUA) by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay is currently investigating arhalofenate in a 12-week Phase 2b clinical trial in patients with gout. The company's second product candidate, MBX-8025 is a potent, selective, orally active PPAR-δ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile that may be useful in the treatment of a variety of rare and orphan diseases currently under evaluation.

For additional information about CymaBay visit www.cymabay.com.

Contact Information